Novavax, Inc. (NASDAQ:NVAX - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Novavax in a note issued to investors on Thursday, August 28th. HC Wainwright analyst S. Lee anticipates that the biopharmaceutical company will post earnings of ($0.27) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Novavax's current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Novavax's Q4 2025 earnings at ($0.37) EPS and FY2026 earnings at ($0.68) EPS.
Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The firm had revenue of $239.24 million for the quarter, compared to analysts' expectations of $149.19 million. During the same period in the previous year, the firm earned $0.99 EPS. The business's quarterly revenue was down 42.4% on a year-over-year basis.
NVAX has been the topic of several other research reports. Bank of America reiterated an "underperform" rating and issued a $7.00 price target (down previously from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. B. Riley restated a "buy" rating on shares of Novavax in a research report on Monday, May 19th. Citigroup assumed coverage on Novavax in a research report on Tuesday, June 17th. They set a "sell" rating and a $6.00 target price for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a report on Friday, May 9th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $14.29.
Check Out Our Latest Research Report on NVAX
Novavax Price Performance
NASDAQ NVAX opened at $7.58 on Friday. The stock's 50 day moving average is $7.38 and its 200 day moving average is $7.17. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. Novavax has a 12 month low of $5.01 and a 12 month high of $15.22. The stock has a market cap of $1.23 billion, a PE ratio of 3.32, a P/E/G ratio of 0.10 and a beta of 2.50.
Institutional Investors Weigh In On Novavax
A number of hedge funds have recently made changes to their positions in NVAX. Thrivent Financial for Lutherans bought a new stake in Novavax during the second quarter valued at about $1,321,000. Marex Group plc bought a new stake in shares of Novavax in the 2nd quarter valued at about $296,000. State of Wyoming bought a new stake in shares of Novavax in the 2nd quarter valued at about $52,000. Headlands Technologies LLC purchased a new position in shares of Novavax in the 2nd quarter worth approximately $903,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Novavax by 437.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 37,335 shares of the biopharmaceutical company's stock worth $235,000 after acquiring an additional 30,386 shares in the last quarter. 53.04% of the stock is currently owned by hedge funds and other institutional investors.
About Novavax
(
Get Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
